Drugs · acquisition-cost intelligence
Pramipexole dihydrochloride
· ingredient pramipexoleDopamine agonists· PRAMIPEXOLE DIHYDROCHLORIDE 1.5 mg/1; PRAMIPEXOLE DIHYDROCHLORIDE 2.25 mg/1; PRAMIPEXOLE DIHYDROCHLORIDE .375 mg/1; PRAMIPEXOLE DIHYDROCHLORIDE 3.75 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$1.37
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-10-222026-05-20
Same-ingredient options by acquisition cost
Other pramipexole products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Pramipexole dihydrochloride | $0.05151 | −$1.32 |
| PRAMIPEXOLE | $0.05603 | −$1.32 |
| Pramipexole dihydrochloride | $0.06093 | −$1.31 |
| Pramipexole Dihydrochloride Extended-Release | $1.00 | −$0.37100 |
Medicare Part D coverage · CY2026
On 41 plan formularies · typical tier 4
Prior auth 0% · Step therapy 7% · Quantity limit 20% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.